Biggest gainers and losers for May 4-8, 2026

BioPharma DiveGSK cuts deal with Sino to broaden reach of hepatitis B drug

Endpoints NewsDaiichi eyes almost $15B in oncology sales by 2030 in ADC franchise push

Endpoints NewsNew home for Novo's Parkinson's cell therapy; GSK turns to China for hep B drug

Clinical OMICsBrain-Controlled Hearing Aid Singles Out Voices in a Crowd

BioWorldFirst cruise ship hantavirus genome points to zoonotic spillover

BioWorldBiggest gainers and losers for May 4-8, 2026

Endpoints NewsInhibrx says combo therapy shrank more tumors than Merck's Keytruda alone

FierceBiotechAmid M&A buzz, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase data

FierceBiotechDaiichi Sankyo targets global top 5 oncology rank by 2035, $1.3B efficiency drive in new 5-year plan

PLoS BiologyThe problem with one-size-fits-all medicine: Biological sex and the aging immune system

PLoS BiologyUSP39 promotes antiviral defense through post-transcriptional control of RIG-I and stabilization of STING

BioPharma DiveInhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial